Myelodysplasia (MDS) is often thought of as “pre-leukemia.” Which is kind of misleading, because only some cases of MDS go on to become leukemia; others stay the same and never progress.
In MDS, there is some sort of abnormality in a myeloid stem cell. If you look at the cells in the blood and bone marrow, you’ll see dysmyelopoiesis (the red cells, neutrophils and/or megakaryocytes look abnormal). The neutrophils in the blood often show dysgranulopoiesis (they lack specific granulation) or hypolobulation (there are only a couple segments to the nucleus – or sometimes no segments at all, just a single round nucleus). Check out the neutrophil in the photo above: the cytoplasm is almost clear (certainly not nice and fawn-pink like you’d expect for a segmented neutrophil), and the nucleus doesn’t have nice segments – just a couple poorly-defined lobes.
In addition to the dysmyelopoietic changes, most cases show a macrocytic anemia. This is an important diagnostic feature, and an easy one to remember. If you see an older patient with a macrocytic anemia, MDS is something you should keep in mind (in addition to the more common causes of a macrocytic anemia, such as B12/folate deficiency and ethanol ingestion).
There may be an increase in myeloblasts in the blood or bone marrow – but if so, it’s a small increase (and certainly not more than 20%, which is the cutoff for acute myeloid leukemia).
There are actually a bunch of different kinds of MDS, everything from refractory anemia (which is just what it sounds like: anemia that does not respond to therapy such as B12 or iron) to chronic myelomonocytic leukemia in transformation (which is a bad name, actually, because it’s a type of MDS, not technically a leukemia). You should not try to memorize these subtypes unless you plan to take your hematopathology boards soon (or unless you have a particularly sadistic pathology professor).
The treatment depends on the type of MDS. Lower-grade types (like refractory anemia) rarely transform into acute leukemia, so they are treated more conservatively. Higher-grade types (like chronic myelomonocytic leukemia in transformation) may be treated more aggressively, particularly if they occur in a younger person who can handle chemotherapy well.
Tagsacute leukemia acute lymphoblastic leukemia acute myeloid leukemia acute promyelocytic leukemia Add new tag anemia b cells blood smear bone marrow brain tumors carcinoma cases chronic myelofibrosis chronic myeloid leukemia chronic myeloproliferative disorders coagulation cortisol cytochemistry cytogenetics essential thrombocythemia heart hemophilia immunology infection inflammation kaplan kidney laboratory tests lymphocyte lymphocytes lymphoma macrophages neoplasia neutrophil normal photoblog polycythemia vera red blood cells red cells sickle cell anemia skin squamous cell carcinoma stains student questions t cells
- Anton said Big thanks!
- Sannie said really enlightening..I actually picked A
- Kristine said Thanks, Joyce – yes – you are absolutely correct: the PTT tests the intrinsic pathway an...
- Simon Downes said Thank you! This was driving me crazy! Now I will never forget it!! I will share it with my buddies!
- Ana Maramadaumasu said This answers my question and i can understand better than what i learn in school,,,thank you very mu...
- Sri said Thank you for the detailed explanation.. It is so clear and creates an enthusiasm to read all the to...
- Joyce said Kristine, this is regarding your comment to Janarthan on 8/3/15 @1:10PM. You seem to have the intrin...
- madelyn said thank you!!!!! You made this seem so simple! =)
- Nisha said Perfectttttttt explanation!!!
- chis said very simple and power-packed explanation! i really appreciate that.
- Trude said Wow, thanks! I believe this also rules for other mutations in tumor suppressos genes. I have been se...
- joly said hi….tanx for coment